Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy. One day ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cuts its guidance ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...